Hey all, welcome back to the real-life pharmacology podcast. I'm your host, pharmacist, Derek Christensen.

Thank you so much for listening today. So always go check out real-life pharmacology.com.

Grab your free 31-page PDF on the top 200 drugs.

Great little study guide if you're taking pharmacology classes or a great little refresher, if you're out in clinical practice,

just some of the most important things you're going to come across in real life,

as well as things that certainly show up on pharmacology and board exams throughout your career as well.

So again, go check that out, real life pharmacology.com, simply an email.

We'll get you access to that. And then we'll get you

info out when we have new things available, such as a podcast like this episode. All right,

let's get into the drug of the day today, and that is Cephyroxime. Brand name of this medication

is Seftin, and it is a a second generation cephalosporin.

So if you remember with cephalosporins, kind of in general, the higher the generation you go up,

it tends to maybe have a little bit more coverage and maybe a little bit more gram-negative coverage.

Cephroxene being a second-generation cephalosporin,

really the most common coverage we're going to have here is gram-positive infections.

You can think of it along the lines of, or at least pretty similar to something like amoxicillin, for example.

Mechanistically, cephalosporins work similar to penicillin antibiotics as well.

So they inhibit bacterial cell wall production, and they do this by binding penicillin binding proteins.

And ultimately, this blocks the final step of peptidoglycan synthesis.

And that peptidoglycan is a part or basically what forms the bacterial cell wall.

So if the bacteria can't form its cell wall, obviously that's going to cause death of the bacteria,

which is what we're trying to do when we try to treat infections here.

...